EGFR therapeutic antibodies such as cetuximab and panitumumab can inhibit the binding of ligands to EGFR and suppress EGFR signaling, and have been approved by the FDA for the treatment of head and neck cancer and metastatic colorectal cancer [13]. The gene discussed is EGFR; the disease is metastatic colorectal cancer.